证券代码：603739 证券简称：蔚蓝生物 公告编号：2024-045 青岛蔚蓝生物股份有限公司 关于终止实施 2021 年股票期权激励计划 暨注销股票期权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2024 年 9 月 19 日，青岛蔚蓝生物股份有限公司（以下简称"公司"）召开 了第五届董事会第十二次会议和第五届监事会第七次会议，分别审议和审议通过 了《关于终止实施 2021 年股票期权激励计划暨注销股票期权的议案》。根据《青 岛蔚蓝生物股份有限公司董事会议事规则》的规定，因出席董事会会议的非关联 董事不足 3 人，该议案将直接提交公司股东大会审议。现将有关事项说明如下： 一、2021 年股票期权激励计划已履行的相关程序 1、2021 年 6 月 24 日，公司第四届董事会第九次会议审议通过了《关于<公 司 2021 年股票期权激励计划（草案）>及其摘要的议案》《关于<公司 2021 年股 票期权激励计划实施考核管理办法>的议案》《关于提请股东大会授权董事会办 理公司 2021 年股票期权激励计划有关事项的议案》。 ...

董事会秘书工作细则 第一章 总则 第一条 为提高青岛蔚蓝生物股份有限公司（以下简称"公司"）的规范运 作水平，充分发挥董事会秘书的作用，加强对董事会秘书工作的管理与监督，根 据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证 券法》（以下简称"《证券法》"）《上海证券交易所股票上市规则》（以下简 称"《上市规则》"）《上海证券交易所上市公司自律监管指引第 1 号——规范 运作》等法律法规和《青岛蔚蓝生物股份有限公司章程》（以下简称"公司章程"） 的有关规定，特制订本细则。 第二条 公司设董事会秘书一名。公司董事会秘书为公司高级管理人员，对 公司和董事会负责，应忠实、勤勉地履行职责。 第三条 公司董事会秘书是公司与上海证券交易所之间的指定联络人，由董 事会秘书、证券事务代表或代行董事会秘书职责的人员以公司名义办理信息披 露、股票及其衍生品种变动管理等事务。 第四条 公司设立董事会办公室，负责协助董事会秘书完成相关工作。董事 会秘书为公司董事会办公室负责人。 青岛蔚蓝生物股份有限公司 第二章 选任 第五条 公司董事会应当在公司首次公开发行股票上市后三个月内，或原任 董事会秘书离职后三个月内聘任 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][3]. Core Views - The company reported a revenue of 609 million yuan in the first half of 2024, representing a year-on-year increase of 12%. However, the net profit attributable to the parent company was 29 million yuan, down 6.73% year-on-year [2]. - The gross margin for the first half of 2024 was 44.77%, a slight increase of 0.59 percentage points year-on-year. Research and development expenses amounted to 55 million yuan, accounting for 9.04% of revenue, which is a 7.06% increase year-on-year [2]. - The enzyme preparation business continued its strong performance, with revenue growth of 20.42% year-on-year. The company has developed four efficient protein expression systems and established a leading high-throughput screening workstation [2]. - The company follows a "technology-driven development" strategy, focusing on independent research and development while also engaging in collaborative research. As of the report date, the company holds 419 domestic authorized invention patents and 10 U.S. patents [2]. - The company has completed its capacity layout across various business segments, with several projects now in operation. The production line for refined enzyme products is expected to commence operations by December 2024 [2]. - The company’s enzyme products have contributed to a reduction of approximately 1.2548 million tons of CO2 emissions in downstream applications during the first half of 2024 [2]. Financial Summary - The company’s revenue forecast for 2024-2026 is projected at 12.73 billion yuan, 13.99 billion yuan, and 15.58 billion yuan respectively, with net profits of 1.00 billion yuan, 1.18 billion yuan, and 1.38 billion yuan for the same period [3]. - The current price-to-earnings (P/E) ratio is 26.3 for 2024, decreasing to 19.0 by 2026, indicating a positive trend in valuation [3]. - The return on equity (ROE) is expected to increase from 4.4% in 2023 to 6.5% in 2026, reflecting improved profitability [3].

Investment Rating - The report maintains an "Outperform the Market" rating for the company [1][3][12] Core Views - The company achieved a steady revenue growth of 12% year-on-year in H1 2024, reaching 609 million yuan, while net profit attributable to shareholders decreased by 6.73% to 29 million yuan [1][6] - The company is focused on technological innovation and aims to establish itself as a global industrial biotechnology platform, with R&D investment of 55.05 million yuan, accounting for 9.04% of revenue, which is relatively high in the industry [1][6] - The enzyme preparation segment showed strong performance with a 21% year-on-year revenue increase to 230 million yuan, while animal health and microecology segments experienced declines [1][8] - The company is enhancing its animal health system and has developed a comprehensive empowerment platform combining "industry + service" [1][6] - The partnership with ADM, a Fortune 500 company, is deepening, with significant progress in joint laboratory projects moving towards product development [1][9] Financial Forecasts and Metrics - Revenue projections for 2024-2026 are estimated at 1.259 billion yuan, 1.329 billion yuan, and 1.407 billion yuan, respectively, with corresponding net profits of 85 million yuan, 91 million yuan, and 97 million yuan [2][12] - The expected earnings per share (EPS) for 2024-2026 are 0.34 yuan, 0.36 yuan, and 0.38 yuan, with price-to-earnings (PE) ratios of 41, 39, and 36 times [2][12] - The company’s gross margin improved by 0.59 percentage points to 44.77% in H1 2024, while the net margin increased by 0.16 percentage points to 6.94% [9][10]

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a positive outlook for future growth [1]. Core Viewpoints - The company achieved a revenue of 609 million yuan in the first half of 2024, representing a year-on-year growth of 12.00%. However, the net profit attributable to shareholders decreased by 6.73% to 29 million yuan [1]. - The company continues to focus on technological innovation, with R&D expenses reaching 55 million yuan, accounting for 9.04% of revenue, an increase of 7.06% year-on-year [1]. - The company has completed its capacity layout, enhancing its multi-business synergy, with various projects operational as of June 2024 [1]. - The enzyme and probiotic industries have high barriers to entry, and the company is well-positioned as a representative enterprise in these fields, with significant technological and platform advantages [1]. Financial Performance Summary - For the second quarter of 2024, the company reported a revenue of 322 million yuan, a year-on-year increase of 3.55%, while the net profit attributable to shareholders fell by 20.46% to 17 million yuan [1]. - The company forecasts net profits of 98 million yuan, 109 million yuan, and 122 million yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 0.39 yuan, 0.43 yuan, and 0.48 yuan [2][4]. - The current price as of August 27, 2024, is 10.57 yuan, with projected PE ratios of 27X, 25X, and 22X for the next three years [3][4].

证券代码：603739 证券简称：蔚蓝生物 公告编号：2024-039 青岛蔚蓝生物股份有限公司 2024 年度第二季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 青岛蔚蓝生物股份有限公司（以下简称"公司"）根据上海证券交易所《上 市公司行业信息披露指引第十四号——食品制造》的要求，现将公司 2024 年第 二季度主要经营数据披露如下： | | 分类 | 年第二季度营业收入（元） 2024 | | | --- | --- | --- | --- | | 产品类别 | 酶制剂 | | 118,676,851.25 | | | 微生态制剂 | | 53,237,710.22 | | | 其他 | | 62,843,545.03 | | | 合计 | | 234,758,106.50 | | 销售模式 | 直销 | | 147,010,348.31 | | | 经销 | | 87,747,758.19 | | | 合计 | | 234,758,106.50 | | 地区分部 | 境外 | | 23,418,16 ...

Financial Performance - The company's operating revenue for the first half of 2024 reached CNY 609,232,865.60, representing a 12.00% increase compared to CNY 543,942,046.84 in the same period last year[12]. - Net profit attributable to shareholders of the listed company was CNY 29,351,998.09, a decrease of 6.73% from CNY 31,469,626.95 in the previous year[12]. - The net cash flow from operating activities significantly increased by 153.31%, amounting to CNY 52,201,921.44 compared to CNY 20,608,113.87 in the same period last year[12]. - The total assets of the company at the end of the reporting period were CNY 3,054,586,318.33, reflecting a 0.68% increase from CNY 3,034,057,625.33 at the end of the previous year[12]. - The net assets attributable to shareholders of the listed company were CNY 1,714,165,006.85, showing a slight increase of 0.34% from CNY 1,708,293,232.64 at the end of the previous year[12]. - Basic earnings per share remained stable at CNY 0.12, unchanged from the same period last year[13]. - The weighted average return on net assets decreased to 1.71%, down by 0.20 percentage points from 1.91% in the previous year[13]. - The company reported non-recurring gains and losses totaling CNY 13,991,020.20 for the reporting period[14]. Research and Development - The company has established eight technology centers and two laboratories, employing 280 dedicated R&D personnel to drive continuous product development[22]. - The company emphasizes a "technology-driven development" strategy, focusing on independent and collaborative R&D to meet market demands[22]. - The company has formed partnerships with over 20 universities and research institutions, enhancing its resource advantages and technology transfer capabilities[22]. - The company has a strong focus on enzyme preparations, holding a leading position in the domestic enzyme preparation industry with significant technological breakthroughs[27]. - The company has established a comprehensive research and development platform for probiotics, including animal trials and clinical studies[29]. - The company has developed 51 proprietary probiotic strains with applications in gastrointestinal comfort, skin health, and immune function, and has filed 79 invention patents related to probiotics[29]. Market and Product Development - The company focuses on the research, production, and sales of enzyme preparations, micro-ecological preparations, and animal health products, aiming to provide core technology support for biomanufacturing and clean energy solutions for traditional industries[15]. - The enzyme and microecological agents market is in a growth phase, with a projected annual market growth rate exceeding 5%, potentially reaching hundreds of billions in the next five years[25]. - The market for biological fungicides is currently valued at approximately 12 billion RMB, with expectations for significant growth driven by environmental policies[25]. - The company is focused on expanding its market presence and developing new technologies to enhance product offerings and operational efficiency[15]. - The company has launched a joint venture with Evonik in January 2024 to enhance animal disease resistance through functional composite microbial preparations[28]. Environmental Commitment - The company is committed to sustainable agriculture through the use of plant micro-ecological preparations, which enhance soil quality and reduce chemical fertilizer usage[20]. - The company’s enzyme technology promotes significant energy savings and reduces carbon emissions in downstream industries[53]. - The company’s micro-ecological products effectively lower the discharge of nitrogen, phosphorus, and other pollutants from livestock manure[53]. - The company has implemented carbon reduction measures, achieving a reduction of 125.48 thousand tons of CO2 equivalent emissions[55]. - The company strictly complies with national environmental protection laws and regulations, ensuring its operations meet environmental standards[51]. Financial Strategy and Investments - The company's R&D investment amounted to CNY 55.05 million, accounting for 9.04% of operating revenue, with a year-on-year increase of 7.06%[36]. - Long-term borrowings increased by 58.72% to ¥98,500,000.00, reflecting the company's strategy to finance growth through debt[43]. - The company has completed the capacity layout for its major business segments, with production operations initiated for several projects, including the animal health industry park[40]. - The company has established a joint venture with Evonik Industries, enhancing its micro-ecological product offerings and market reach[35]. - The company has committed to maintaining a debt-to-equity ratio below 0.5 to ensure financial stability[60]. Risks and Challenges - The company faces market competition risks in the enzyme preparation and animal protection industries, which could impact future performance if not addressed[47]. - The company is exposed to risks from livestock diseases and natural disasters, which can lead to decreased demand for feed additives and related products[47]. - Raw material price volatility poses a significant risk to production costs, potentially impacting profitability[47]. - The company is at risk of foreign exchange losses due to export products being settled in USD, with potential impacts on pricing competitiveness[48]. Shareholder and Corporate Governance - The company has not disclosed any plans for new product development or market expansion in the current report[4]. - No profit distribution or capital reserve increase plans are proposed for the half-year period[49]. - The company has implemented stock incentive plans, with no recent changes reported[49]. - The controlling shareholder has committed to not transferring shares for 36 months post-IPO, with specific conditions for share price adjustments[58]. - The company has not reported any changes in major shareholders or actual controllers during the reporting period[71].

青岛蔚蓝生物股份有限公司 重大信息内部报告制度 第一章 总则 第一条 为规范青岛蔚蓝生物股份有限公司（以下简称 "公司"）的重大信 息内部报告工作，保证公司内部重大信息的快速传递、归集和有效管理，确保公 司真实、准确、完整、及时、公平地披露所有对公司股票及其衍生品种交易价格 可能产生较大影响的信息，维护投资者的合法权益，为公司决策提供科学依据， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《上市公司信息披露管理办法》（以 下简称"《管理办法》"）、《上海证券交易所股票上市规则》（以下简称"《上 市规则》"）等法律法规、规范性文件及《青岛蔚蓝生物股份有限公司章程》（以 下简称"《公司章程》"），结合公司实际情况，制定本制度。 第二条 公司重大信息内部报告制度是指当出现、发生或即将发生可能对 公司股票及其衍生品种交易价格产生较大影响的情形或事件时，按照本制度规定 的重大信息报告义务人，应当在第一时间将有关重大信息向董事会秘书、董事长 和董事会报告的制度。 第三条 本制度适用于公司、全资子公司、控股子公司及参股公司等。本制 度所称"重大信息报告义务人 ...

青岛蔚蓝生物股份有限公司董事、监事和高级管理人员 所持本公司股份及其变动管理制度 第一条 为加强青岛蔚蓝生物股份有限公司（以下简称"公司"）董事、监 事和高级管理人员所持公司股份及买卖公司股票行为的管理，根据《中华人民共 和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证 券法》"）《上市公司股东减持股份管理暂行办法》《上市公司董事、监事和高级管 理人员所持本公司股份及其变动管理规则》《上海证券交易所上市公司自律监管 指引第 8 号——股份变动管理》《上海证券交易所上市公司自律监管指引第 15 号——股东及董事、监事、高级管理人员减持股份》等法律法规和《青岛蔚蓝生 物股份有限公司章程》（以下简称"《公司章程》"）的规定，制定本制度。 第二条 本办法适用于公司董事、监事和高级管理人员，其所持本公司股份 是指登记在其名下和利用他人账户持有的所有本公司股份。公司董事、监事和高 级管理人员从事融资融券交易的，其所持本公司股份还包括记载在其信用账户内 的本公司股份。 第三条 存在下列情形之一的，公司董事、监事和高级管理人员所持本公司 股份不得转让： （一）本公司股票上市交易之日起 1 年内； ...

（三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 青岛蔚蓝生物股份有限公司 舆情管理制度 第一章 总则 第一条 为了提高青岛蔚蓝生物股份有限公司（以下简称"公司"）应对各类 舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司股 票及其衍生品种、公司商业信誉及正常生产经营活动造成的影响，切实保护投资 者合法权益，根据相关法律法规和《青岛蔚蓝生物股份有限公司章程》（以下简 称"《公司章程》"）的规定，特制订本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； 第二章 舆情管理的组织体系及其工作职责 第三条 公司应对各类舆情实行统一领导、统一组织、快速反应、协同应对。 第四条 公司成立应对舆情管理工作领导小组（以下简称"舆情工作组"）， 由公司董事长任组长，董事会秘书担任副组长，成员由公司其他高级管理人员及 相关职能部门负责人组成。 第五条 舆情工作组是公司应对各类舆情处理工作的领导机构，统 ...